North America Bovine Respiratory Disease Treatment Market

North America Bovine Respiratory Disease Treatment Market Size (2023 to 2028)

The North America Bovine Respiratory Disease Treatment Market was estimated at USD 16.94 million in 2022. It is further projected to reach USD 39.25 million by 2027, growing at a CAGR of 18.3% during the forecast period. The U.S. feedlot industry estimates a huge annual loss for bovine respiratory disease (BRD) due to loss of production, increased labor expenses, pharmaceutical costs, and death deriving from BRD. 

BRD refers to any disease of the lower or upper respiratory tracts in cattle and is commonly associated with lung infections, which can cause pneumonia. Bovine Respiratory Disease is far too common, far too costly, and, for the most part, seems far too hard to handle. If cattle are treated more than once, they never get back to that peak performance.

The disease is caused by various factors such as Host factors, which include animal age, immunity, genetics, and exposure to pathogens; environmental factors involve crowding, temperature, commingling and transport, Internal or external parasite infections, and Infectious agents. The weight loss that animal has due to BRD sickness will stay with them throughout the feeding period. Hence, productivity is reduced. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and are expected to improve the treatment's success rate.

This research report segmented and sub-segmented the North America Bovine Respiratory Disease Treatment Market into the following categories:

By Treatment Type: 

• Anti-Infectious Agents
  • Antibiotics           
  • Sulfas    
• Anti-Parasiticides                 
• Bronchodilators                    
• Oral Rehydration Fluids                     
• Non-Steroidal Anti-Inflammatories               
• Mucolytics

By Country: 

• The United States
• Canada
• Rest of North America

Some of the promising companies operating in the North American Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.